Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
Triggers euro 2.5 Million (~$3 Million) Milestone Payment from Gedeon Richter CRANBURY, N.J., Dec. 29, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program. …
Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction Read More »